Skip to main content
OpenTrials
Completed

NCT Number: NCT00562549

Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension

The purpose is to determine the effective dosage and to study the effects of this dosage taken for 12 days on systolic and diastolic blood pressure in patients with hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Addenbrooke's Hospital

Cambridge, CB2 2QQ, United Kingdom

About this study

  • Office seated peripheral systolic and diastolic blood pressure
  • Adverse events and vital signs
  • Plasma concentrations of SLx-2101

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or females between 18 and 80 years, inclusive
  • Moderate to severe hypertension
  • Body weight within a body mass index range of 18 - 32 kg/m2

Exclusion criteria

  • Subject is receiving more than four antihypertensive agents
  • History of drug abuse
  • Exposure to a new chemical entity within 3 months prior to the first day of dosing

Treatment and study plan

SLx-2101

Drug

Primary outcomes

  1. Office seated peripheral systolic and diastolic blood pressure

    Time frame: 12 days

Secondary outcomes

  1. Adverse events and changes in vital signs

    Time frame: 12 days

Sponsors and collaborators

Lead sponsor

Retension Pharmaceuticals. Inc.

Industry

Registry information

Official study title

A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5, 10 or 20 mg Once Daily for up to 14 Days in Patients With Hypertension

Important dates

Study start
2007
Primary completion
2007
Study completion
2007
First posted
Nov 22, 2007
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.